 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || MBS8 / MonTa Biosciences
Trial completion date, Trial primary completion date, Metastases: Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours (clinicaltrials.gov) - Oct 19, 2023
P1, N=69, Recruiting, Sponsor: MonTa Biosciences ApS
Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
- MBS8 / MonTa Biosciences
Efficacy and safety of the TLR7 agonist micelles MBS8(1V270) tested in pre-clinical models (Section 23; Poster Board #24) - Mar 14, 2023 - Abstract #AACR2023AACR_3969;
P1
Together, these data provide a rationale for clinical studies of MBS8(1V270) as monotherapy and in combination with immune checkpoint inhibitors. MBS8(1V270) is currently under clinical investigation in the clinical trial MBS8-101 (ClinicalTrials.gov identifier NCT04855435).
- || MBS8 / MonTa Biosciences
Trial completion date, Trial primary completion date, Metastases: Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours (clinicaltrials.gov) - Nov 2, 2022
P1, N=69, Recruiting, Sponsor: MonTa Biosciences ApS
MBS8(1V270) is currently under clinical investigation in the clinical trial MBS8-101 (ClinicalTrials.gov identifier NCT04855435). Trial completion date: Nov 2022 --> Apr 2023 | Trial primary completion date: Oct 2022 --> Apr 2023
- MBS8 / MonTa Biosciences, Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Systemic administration of TLR7/8 agonist micelles triggers a potent anti-tumor response mediated by neutrophils as primary effector cells followed by establishment of an immune memory response (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1477;
P1
Further, an adaptive immune response was initiated including generation of tumor antigen-specific CD8 + cells and establishment of immune memory response. MBS8 was well tolerated in rodents and cynomolgus monkeys at dose levels above therapeutic effective doses identified in mice, thus providing a good therapeutic window.
- MBS8 / MonTa Biosciences, Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Systemic TLR7/8 micelles trigger a novel and potent anti-tumor response by strong recruitment of neutrophils leading to massive tumor cell killing. (Available On Demand; 231) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1636;
P1
MBS8 demonstrated a novel mode of action with neutrophils playing a central role as primary effector cells causing a rapid killing of tumors. Further, adaptive immune response was initiated including generation of tumor specific CD8+ cells and establishment of the immune memory.
- | MBS8 / MonTa Biosciences
New P1 trial, Metastases: Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours (clinicaltrials.gov) - Apr 22, 2021
P1, N=69, Recruiting, Sponsor: MonTa Biosciences ApS